Industry News
Pharmaceutical Industry News
Los fármacos de acción prolongada podrían revolucionar el tratamiento de VIH
Nuevos tratamientos en desarrollo, que incluyen píldoras de una vez a la semana e inyecciones semestrales, ayudarían a controlar el virus en poblaciones de difícil acceso.
Addiction Risk Scores Won’t Solve the Opioid Crisis
A number of new tech companies want to solve the opioid crisis with algorithms. It’s a flawed and potentially harmful proposition.
Inside Novo Nordisk’s Headquarters
Ozempic and Wegovy, the diabetes and weight-loss drugs, have soared to celebrity status in the U.S. But Novo Nordisk, the Danish company behind them, can’t make enough of them. The New York Times reporter Eshe
How Ozempic Is Transforming a Small Danish Town
In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment
New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.
Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports
The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy.
Why Is There a Tick Vaccine For Dogs and Not Humans?
Certain concerns have hindered development, but several Lyme prevention drugs are currently being tested in humans.
David Egilman, Doctor Who Took On Drug Companies, Dies at 71
His testimony as an expert witness in some 600 trials helped plaintiffs win billions of dollars in cases involving malfeasance by pharmaceutical makers.
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for
La nueva realidad mundial del dengue exige encontrar una mejor vacuna
Los gobiernos de América Latina han confirmado más de 3,5 millones de casos de dengue en los tres primeros meses de 2024, frente a los 4,5 millones de todo 2023. Es una advertencia de un
The Push for a Better Dengue Vaccine Grows More Urgent
A public research institute in Brazil has proved a new shot protects against the disease, but can’t make it fast enough to stop the huge outbreak sweeping Latin America.
Global Stockpile of Cholera Vaccine Is Gone as Outbreaks Spread
One company is going to great lengths to build it up, but it will be years before it returns to the minimum level.
Regulating Opioid Prescriptions
Pain management is an inexact science; there is plenty of blame to go around for the abuse of such drugs.
Un estudiomostró que se puede frenar el párkinson con lixisenatida
El ensayo duró solo un año y no es concluyente, pero dio señales de esperanza a algunos expertos.
A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says
Results of a large clinical trial found the treatment did not work any better than a placebo.
Amid Recalls, Are Eye Drops Safe to Use?
Here’s why some products have been pulled from store shelves, and what to know to protect your eyes.
An Ozempic Relative Slowed Parkinson’s Disease in a Small Study
The trial lasted only one year but offered embers of hope to some experts.
El caso sobre las píldoras abortivas en la Corte Suprema en 4 conclusiones
Varios jueces cuestionaron la conveniencia de aplicar restricciones nacionales a la mifepristona porque sería la primera vez que un tribunal cuestiona el juicio de los expertos de la FDA sobre un medicamento.
Supreme Court Seems Inclined to Reject Bid to Curtail Abortion Pill Access
A majority of the justices questioned whether a group of anti-abortion doctors and organizations trying to sharply limit availability of the medication could show they suffered harm.